TransMedics Group’s (TMDX) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of TransMedics Group (NASDAQ:TMDX) in a report published on Tuesday,Benzinga reports. The firm currently has a $125.00 price target on the stock.

A number of other analysts have also recently commented on the company. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday. Robert W. Baird cut their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Finally, Piper Sandler reduced their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $66.25 on Tuesday. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 70.48 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a one year low of $66.10 and a one year high of $177.37. The company’s 50-day moving average is $105.43 and its 200 day moving average is $134.42.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period last year, the company posted ($0.12) earnings per share. The business’s revenue was up 63.7% compared to the same quarter last year. Sell-side analysts expect that TransMedics Group will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,042 shares of company stock worth $3,563,985. 7.00% of the stock is owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently bought and sold shares of the business. Vaughan Nelson Investment Management L.P. purchased a new position in shares of TransMedics Group in the 2nd quarter worth $39,862,000. Driehaus Capital Management LLC lifted its holdings in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the last quarter. Principal Financial Group Inc. grew its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Hood River Capital Management LLC bought a new stake in TransMedics Group during the second quarter worth approximately $18,854,000. Finally, Canada Pension Plan Investment Board purchased a new stake in TransMedics Group during the second quarter valued at approximately $16,086,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.